Heparanase activation induces epidermal hyperplasia, angiogenesis, lymphangiogenesis and wrinkles

Experimental Dermatology

Volumn 19, Issue 11, 2010, Pages 965-972

  Iriyama, Shunsuke ^a   Matsunaga, Yukiko ^a   Amano, Satoshi ^a  

^a SHISEIDO RESEARCH CENTER   (Japan)

Author keywords

Angiogenesis; Barrier disruption; Keratinocyte; Wrinkle formation

Indexed keywords

1 [4 (1H BENZOIMIDAZOL 2 YL)PHENYL] 3 [4 (1H BENZOIMIDAZOL AZOL 2 YL)PHENYL]; GLYCOSIDASE INHIBITOR; HEPARAN SULFATE; HEPARANASE; PERLECAN; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN C;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DERMOEPIDERMAL JUNCTION; ENZYME ACTIVATION; EPIDERMIS; EPIDERMIS HYPERPLASIA; GENE EXPRESSION; IC 50; LYMPH VESSEL; LYMPHANGIOGENESIS; MALE; MOUSE; NONHUMAN; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN BLOOD VESSEL; SKIN INJURY; WRINKLE;

ANIMALS; BASEMENT MEMBRANE; DERMIS; ENZYME INHIBITORS; EPIDERMIS; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 7; GENE EXPRESSION; GLUCURONIDASE; HEPARAN SULFATE PROTEOGLYCANS; HEPARITIN SULFATE; HYPERPLASIA; LYMPHANGIOGENESIS; MALE; MICE; MICE, HAIRLESS; NEOVASCULARIZATION, PATHOLOGIC; SKIN; SKIN AGING; THROMBOSPONDIN 1; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 77958602423     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2009.01027.x     Document Type: Article

References (50)

1. Denda M, Inoue K, Fuziwara S, Denda S. P2X purinergic receptor antagonist accelerates skin barrier repair and prevents epidermal hyperplasia induced by skin barrier disruption. J Invest Dermatol 2002: 119: 1034-1040.
2. Denda M. New strategies to improve skin barrier homeostasis. Adv Drug Deliv Rev 2002: 54 (Suppl. 1): S123-S130.
3. Matsunaga Y, Ogura Y, Ehama R, Amano S, Nishiyama T, Tagami H. Establishment of a mouse skin model of the lichenification in human chronic eczematous dermatitis. Br J Dermatol 2007: 156: 884-891.
4. Yano K, Kajiya K, Ishiwata M, Hong Y K, Miyakawa T, Detmar M. Ultraviolet B-induced skin angiogenesis is associated with a switch in the balance of vascular endothelial growth factor and thrombospondin-1 expression. J Invest Dermatol 2004: 122: 201-208.
5. Hirakawa S, Fujii S, Kajiya K, Yano K, Detmar M. Vascular endothelial growth factor promotes sensitivity to ultraviolet B-induced cutaneous photodamage. Blood 2005: 105: 2392-2399.
6. Yano K, Oura H, Detmar M. Targeted overexpression of the angiogenesis inhibitor thrombospondin-1 in the epidermis of transgenic mice prevents ultraviolet-B-induced angiogenesis and cutaneous photo-damage. J Invest Dermatol 2002: 118: 800-805.
7. Yano K, Kadoya K, Kajiya K, Hong Y K, Detmar M. Ultraviolet B irradiation of human skin induces an angiogenic switch that is mediated by upregulation of vascular endothelial growth factor and by downregulation of thrombospondin-1. Br J Dermatol 2005: 152: 115-121.
8. Witte M H, Bernas M J, Martin C P, Witte C L. Lymphangiogenesis and lymphangiodysplasia: from molecular to clinical lymphology. Microsc Res Tech 2001: 55: 122-145.
9. Oliver G, Detmar M. The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. Genes Dev 2002: 16: 773-783.
10. Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev 2002: 82: 673-700.
11. Makinen T, Jussila L, Veikkola T et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 2001: 7: 199-205.
12. Kajiya K, Hirakawa S, Detmar M. Vascular endothelial growth factor-A mediates ultraviolet B-induced impairment of lymphatic vessel function. Am J Pathol 2006: 169: 1496-1503.
13. Cueni L N, Detmar M. New insights into the molecular control of the lymphatic vascular system and its role in disease. J Invest Dermatol 2006: 126: 2167-2177.
14. Patel V N, Knox S M, Likar K M et al. Heparanase cleavage of perlecan heparan sulfate modulates FGF10 activity during ex vivo submandibular gland branching morphogenesis. Development 2007: 134: 4177-4186.
15. Kan M, Wu X, Wang F, McKeehan W L. Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase. J Biol Chem 1999: 274: 15947-15952.
16. Kreuger J, Salmivirta M, Sturiale L, Gimenez-Gallego G, Lindahl U. Sequence analysis of heparan sulfate epitopes with graded affinities for fibroblast growth factors 1 and 2. J Biol Chem 2001: 276: 30744-30752.
17. Luo Y, Ye S, Kan M, McKeehan W L. Control of fibroblast growth factor (FGF) 7- and FGF1-induced mitogenesis and downstream signaling by distinct heparin octasaccharide motifs. J Biol Chem 2006: 281: 21052-21061.
18. Freeman C, Liu L, Banwell M G et al. Use of sulfated linked cyclitols as heparan sulfate mimetics to probe the heparin/heparan sulfate binding specificity of proteins. J Biol Chem 2005: 280: 8842-8849.
19. Tammela T, He Y, Lyytikka J et al. Distinct architecture of lymphatic vessels induced by chimeric vascular endothelial growth factor-C/vascular endothelial growth factor heparin-binding domain fusion proteins. Circ Res 2007: 100: 1468-1475.
20. Ashikari-Hada S, Habuchi H, Kariya Y, Itoh N, Reddi A H, Kimata K. Characterization of growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library. J Biol Chem 2004: 279: 12346-12354.
21. Perrimon N, Bernfield M. Specificities of heparan sulfate proteoglycans in developmental processes. Nature 2000: 404: 725-728.
22. Elkin M, Ilan N, Ishai-Michaeli R, et al. Heparanase as mediator of angiogenesis: mode of action. FASEB J 2001: 15: 1661-1663.
23. Nakajima M, Irimura T, Di Ferrante N, Nicolson G L. Metastatic melanoma cell heparanase. Characterization of heparan sulfate degradation fragments produced by B16 melanoma endoglucuronidase. J Biol Chem 1984: 259: 2283-2290.
24. Freeman C, Parish C R. Human platelet heparanase: purification, characterization and catalytic activity. Biochem J 1998: 330: 1341-1350.
25. Pikas D S, Li J P, Vlodavsky I, Lindahl U. Substrate specificity of heparanases from human hepatoma and platelets. J Biol Chem 1998: 273: 18770-18777.
26. Kato M, Wang H, Kainulainen V, et al. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nature Med 1998: 4: 691-697.
27. Parish C R, Freeman C, Hulett M D. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 2001: 1471: M99-M108.
28. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001: 108: 341-347.
29. Bernard D, Mehul B, Delattre C, Simonetti L, Thomas-Collignon A, Schmidt R. Purification and characterization of the endoglycosidase heparanase 1 from human plantar stratum corneum: a key enzyme in epidermal physiology? J Invest Dermatol 2001: 117: 1266-1273.
30. Malgouries S, Donovan M, Thibaut S, Bernard B A. Heparanase 1: a key participant of inner root sheath differentiation program and hair follicle homeostasis. Exp Dermatol 2008: 17: 1017-1023.
31. Zcharia E, Zilka R, Yaar A, et al. Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models. FASEB J 2005: 19: 211-221.
32. Gingis-Velitski S, Ishai-Michaeli R, Vlodavsky I, Ilan N. Anti-heparanase monoclonal antibody enhances heparanase enzymatic activity and facilitates wound healing. FASEB J 2007: 21: 3986-3993.
33. Kobayashi M, Naomoto Y, Nobuhisa T, et al. Heparanase regulates esophageal keratinocyte differentiation through nuclear translocation and heparan sulfate cleavage. Differentiation 2006: 74: 235-243.
34. Pan W, Miao H Q, Xu Y J, et al. 1-[4-(1H-Benzoimidazol-2-yl)-phenyl]-3-[4-(1H-benzoimidazol-2-yl)-phenyl]- urea derivatives as small molecule heparanase inhibitors. Bioorg Med Chem Lett 2006: 16: 409-412.
35. Inomata S, Matsunaga Y, Amano S, et al. Possible involvement of gelatinases in basement membrane damage and wrinkle formation in chronically ultraviolet B-exposed hairless mouse. J Invest Dermatol 2003: 120: 128-134.
36. Friedl A, Chang Z, Tierney A, Rapraeger A C. Differential binding of fibroblast growth factor-2 and -7 to basement membrane heparan sulfate: comparison of normal and abnormal human tissues. Am J Pathol 1997: 150: 1443-1455.
37. Behzad F, Brenchley P E. A multiwell format assay for heparanase. Anal Biochem 2003: 320: 207-213.
38. Simizu S, Ishida K, Wierzba M K, Sato T A, Osada H. Expression of heparanase in human tumor cell lines and human head and neck tumors. Cancer Lett 2003: 193: 83-89.
39. Ishida K, Hirai G, Murakami K, et al. Structure-based design of a selective heparanase inhibitor as an antimetastatic agent. Mol Cancer Ther 2004: 3: 1069-1077.
40. Vlodavsky I, Miao H Q, Medalion B, Danagher P, Ron D. Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Cancer Metastasis Rev 1996: 15: 177-186.
41. Whitelock J M, Iozzo R V. Heparan sulfate: a complex polymer charged with biological activity. Chem Rev 2005: 105: 2745-2764.
42. Maas-Szabowski N, Shimotoyodome A, Fusenig N E. Keratinocyte growth regulation in fibroblast cocultures via a double paracrine mechanism. J Cell Sci 1999: 112: 1843-1853.
43. Shafat I, Vlodavsky I, Ilan N. Characterization of mechanisms involved in secretion of active heparanase. J Biol Chem 2006: 281: 23804-23811.
44. Abboud-Jarrous G, Atzmon R, Peretz T, et al. Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J Biol Chem 2008: 283: 18167-18176.
45. Reinheckel T, Hagemann S, Dollwet-Mack S, et al. The lysosomal cysteine protease cathepsin L regulates keratinocyte proliferation by control of growth factor recycling. J Cell Sci 2005: 118: 3387-3395.
46. Detmar M, Brown L F, Claffey K P, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994: 180: 1141-1146.
47. Streit M, Velasco P, Riccardi L, et al. Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice. EMBO J 2000: 19: 3272-3282.
48. Kishimoto J, Ehama R, Ge Y, et al. In vivo detection of human vascular endothelial growth factor promoter activity in transgenic mouse skin. Am J Pathol 2000: 157: 103-110.
49. Kajiya K, Detmar M. An important role of lymphatic vessels in the control of UVB-induced edema formation and inflammation. J Invest Dermatol 2006: 126: 919-921.
50. Kajiya K, Sawane M, Huggenberger R, Detmar M. Activation of the VEGFR-3 pathway by VEGF-C attenuates UVB-induced edema formation and skin inflammation by promoting lymphangiogenesis. J Invest Dermatol 2009: 129: 1292-1298.